
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences is poised for future success, with a Phase 2 basket study on ABI-6250 targeting cholestatic liver diseases and promising results from their NTCP inhibition. Partnered with Gilead for further development and with regained rights to ABI-4334, the company has a strong financial position and will present additional data on ABI-6250 at the EASL Congress in 2026, indicating potential growth in the future. However, potential risks such as clinical development, Gilead's decision, and regulatory delays must be considered when evaluating the company's $0.9 billion valuation and potential future success.
Bears say
Assembly Biosciences is facing a significant amount of risk with its continued reliance on raising capital to fund operations, as well as potential dilution of current investors' holdings. Additionally, any delays or setbacks in the development and commercialization of its pipeline products could significantly impact the company's sales potential and valuation. While there is potential for data-rich catalysts in 2027, a data-light year in 2026 may not bode well for the company's overall prospects and its ability to generate profits until 2032. Furthermore, while the HDV program remains a top priority, there are also potential challenges in disrupting a historically low market for treatment, and even in a best-case scenario, the estimated peak annual revenues may not be enough to outweigh the risks involved.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares